NNVC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 18:22):

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections...

Stats
Dzisiejszy wolumen	15 640.00
Średni wolumen	29 345.00
Kapitalizacja rynkowa	13.07M
EPS	$0 ( 2024-02-14 )
Następna data zysków	( $-0.190 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.390
ATR14	$0.0270 (2.43%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-08	Diwan Anil	Sell	94 471	Common Stock, par value $0.001 per share
2020-02-07	Jawadakar Makarand	Buy	0
2019-06-02	Day Mark D.	Buy	0
2018-05-21	Boniuk Milton	Buy	5 500 000	Common Stock, par value $0.001 per share
2017-02-21	Boniuk Milton	Buy	1 746 288	Common Stock, par value $0.001 per share

INSIDER POWER
-100.00
Last 95 transactions
Buy: 11 406 507 \| Sell: 1 435 933

NanoViricides Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

NanoViricides Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-747 529 (0.00 %)
EPS:	$-0.740

FY	2023
Przychody:	$0
Zysk brutto:	$-747 529 (0.00 %)
EPS:	$-0.740

FY	2022
Przychody:	$0
Zysk brutto:	$-723 325 (0.00 %)
EPS:	$-0.700

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

NanoViricides Inc

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.